This information is current as of July 16, 2023.

The Forest and the Trees
T.M. Leslie-Mazwi and J.A. Hirsch

*AJNR Am J Neuroradiol* published online 24 September 2020

http://www.ajnr.org/content/early/2020/09/24/ajnr.A6864
Coronavirus disease 2019 (COVID-19) is a multisystem disease, the brain is not spared, and neurologic presentations are increasingly reported. Neurologic symptoms, including headache, altered mental status, and anosmia, occur in many infected patients. Pathologic findings range from white matter disease to encephalitis, with only small samples of pathologic specimens published to date. Thrombosis is common in critically ill patients with COVID-19, and vasculopathy has been described, clinically and pathologically. Given this widespread vascular involvement, the impact of the pandemic on stroke has been a prominent concern. Reports to date suggest large-vessel occlusion (LVO) stroke in unusual populations and friable clot with an increased propensity for clot fragmentation during thrombectomy.

In this issue of the *American Journal of Neuroradiology*, these considerations are further informed by an article by John et al, from a large private medical center in the United Arab Emirates. The authors reviewed the experience of LVO care in patients positive for COVID-19 with stroke from March to May 2020, and compared this with a similar period in 2019. They found, in 2020, an increase in total stroke presentations and in LVOs (20 versus 44 patients, $P = .008$), attributed to changes in referral pathways during the pandemic in the region. Despite increasing case frequency, longer door-to-groin puncture times were seen in 2020 (68 versus 104 minutes, $P = .001$), caused by delays incurred by new safety protocols. A remarkably high rate of LVO in patients positive for COVID-19 with stroke was identified, 75% of COVID-19-associated stroke presentations in this series. Reperfusion was achieved in 67% of patients positive for COVID-19 with LVO undergoing thrombectomy, with excellent groin-to-reperfusion times. Who were these patients? Typically, younger (mean age of 46 years) with a preponderance of men (93%) who lacked traditional vascular risk factors (absent in 60% of the patients). Consistent with prior observations about prothrombotic tendencies, in this sample, a quarter of patients positive for COVID-19 with stroke had additional systemic thrombotic disease, and the burden of LVO clot and the multiplicity of vessels affected were notable. Forty percent of patients had more than a single intracranial arterial vessel affected by thrombosis or occlusion.

These results provide a snapshot of the potential impact of COVID-19 on stroke. The observational literature is growing. The study findings and similar reports have strong pathophysiologic plausibility. However, we must maintain appropriate caution. Beyond small sample sizes, there is the distinct risk of reporting bias in the literature available on COVID-19 and stroke. Reports of similar findings are lacking for other epicenters in China, Europe, and much of the most affected regions in the United States. This finding is surprising given the incidence reported in this and other positive samples. The additional variable of stroke geographies and stroke systems of care is also relevant. These results from Abu Dhabi compare technically very favorably with US or European centers, but stroke populations and systems of care are different, as the authors carefully highlight.

Despite these cautions, it seems likely that stroke presentations are affected directly by the virus. Perhaps this impact is as described in the available literature for particular subpopulations. What should we make of these and similar small series? These findings may have implications for prophylactic measures in patients severely affected by the virus, in whom coagulation abnormalities are widespread. The role of therapeutic dosing of anticoagulation or antiplatelet therapy in patients with COVID-19 prophylactically remains controversial (though clearly deep venous thrombosis prophylaxis is widely indicated). Venous cerebrovascular disease has also been reported, for which anticoagulation clearly has a role, but whether addressing thrombotic risk in patients with COVID-19 impacts arterial stroke rates is unknown. It also seems likely that in patients who are positive for COVID-19 and have an LVO, our thrombectomy expectations must evolve. These patients pose a technical challenge with possibly reduced likelihood of recanalization and the need to treat potentially more than a single circulation. These are points of conjecture currently. Are findings specific to Severe Acute Respiratory Syndrome COVID-19 or should they be expected in any systemic viral illness of this severity, and are they only prominent because of the pandemic nature of this one? This, too, is uncertain.

To understand these questions better, we need large-dataset analysis, looking at incidence rates, therapies, and outcomes. For instance, the American Heart Association/America Stroke Association Get With The Guidelines stroke campaign (https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke) collects data for hospitals treating stroke and will offer a window into this issue as data are progressively collated. This effort will be central to...
our understanding of the broader impact of COVID-19 on stroke pathophysiology, as distinct from its effect in currently reported pockets of patients.

While we may rightly debate the pathophysiology of COVID-19 and stroke, there should be less debate about the impact of COVID-19 on stroke systems of care. The identified decreases in overall stroke presentations are driven largely by a decrease in presentation of patients with milder strokes. Severely affected patients with stroke still present for care, consistent with the findings of John, et al: 75% of acute stroke presentations in their patients with COVID-19 had LVOs. John et al further reported systems approaches in the centralization of care that led to their increased stroke and LVO numbers. Localization of expertise has systems level bears special emphasis. We may experience limitations in our ability to impact stroke in the individual patient with COVID-19. Much remains unknown and may remain unknown. It is well within our power, however, to positively influence the impact of this disease on stroke systems of care. This is the forest, not just the trees. Such system adaptations, when pursued thoughtfully and collaboratively, build a resilient stroke-care system to handle this pandemic, as well as other challenges in the future, despite the numerous uncertainties about stroke mechanisms.

REFERENCES


©T.M. Leslie-Mazwi
Departments of Neurosurgery and Neurology
J.A. Hirsch
Department of Radiology
Massachusetts General Hospital
Boston, Massachusetts

http://dx.doi.org/10.3174/ajnr.A6864